Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more allergens, with the prevalence for short ragweed being 26.2% The purpose of this observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to ragweed allergen in the EEC among subjects who completed all dosing visits and the post treatment challenge (PTC) visit in study TR002 approximately one year after the start of treatment.
Subjects who were randomised in study TR002 and who completed all dosing visits and the PTC will be invited to attend the Screening Visit for TR002B. Subjects will attend the EEC for 4 visits on successive days. Following the final EEC visit a follow-up visit will be performed 3-10 days later.
Study Type
OBSERVATIONAL
Enrollment
109
No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
Cetero Research
Mississauga, Ontario, Canada
Total Rhinoconjunctivitis Symptom Score
Time frame: 48-54 weeks after the start of treatment in TR002
Total nasal and non-nasal symptom scores
Time frame: 48-54 weeks after the start of treatment in TR002
Change in Immunoglobulin A (IgA)
Time frame: 50-56 weeks after the start of treatment in Tr002
Change in Immunoglobulin E (IgE)
Time frame: 50-56 weeks after the start of treatment in Tr002
Change in Immunoglobulin G4 (IgG4)
Time frame: 50-56 weeks after the start of treatment in Tr002
Adverse Events
Time frame: 50-56 weeks after the start of treatment in TR002
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.